Please check your internet connection and try again.
# Ecospirin (Aspirin, Enteric-Coated)
## Overview
Ecospirin is a brand of enteric-coated acetylsalicylic acid (ASA). It acts as an irreversible inhibitor of cyclooxygenase-1 (COX-1), reducing prostaglandins and thromboxane A2, thereby providing antiplatelet, analgesic, antipyretic, and anti-inflammatory effects. Enteric coating reduces direct gastric mucosal irritation but does not eliminate the risk of systemic GI ulceration.
## Primary Indications
* Prophylaxis of myocardial infarction (MI) and stroke.
* Secondary prevention of cardiovascular events.
* Acute coronary syndromes (often chewed, non-enteric preferred in acute settings).
* Management of pain, fever, and inflammatory conditions (e.g., rheumatoid arthritis).
## Adult Dosing
* **Cardiovascular Prophylaxis:** 75 mg to 162 mg orally once daily.
* **Analgesia/Antipyretic:** 325 mg to 650 mg every 4–6 hours as needed.
* **Maximum Dose:** 4 g/day for long-term therapy.
## Pediatric Dosing
* **General Note:** Not recommended for children/teenagers with viral infections due to **Reye’s Syndrome** risk.
* **Kawasaki Disease:** 80–100 mg/kg/day (divided every 6 hours) during the febrile phase, followed by 3–5 mg/kg once daily for antiplatelet effect.
* *Consult local pediatric protocols for institutional-specific Kawasaki dosing guidelines.*
## Dose Adjustments
* **Renal Impairment:** Avoid in severe renal failure (CrCl < 10 mL/min). Use with caution in moderate impairment.
* **Hepatic Impairment:** Avoid in severe liver disease (increased risk of bleeding and encephalopathy).
## Contraindications
* Known hypersensitivity to salicylates or NSAIDs.
* Active peptic ulcer disease or pathological bleeding.
* Children/teenagers with viral infections (influenza/varicella).
* History of asthma/nasal polyps precipitated by aspirin (aspirin-exacerbated respiratory disease).
* Severe thrombocytopenia.
## Adverse Effects
* **GI:** Dyspepsia, nausea, gastric erosion, ulceration, occult bleeding.
* **Hematologic:** Prolonged bleeding time, increased risk of hemorrhagic stroke.
* **Otic:** Tinnitus and hearing loss (usually dose-related/salicylism).
* **Hypersensitivity:** Bronchospasm, urticaria, angioedema.
## Key Drug Interactions
* **Anticoagulants/Antiplatelets (Warfarin, Clopidogrel, DOACs, NSAIDs):** Increased risk of major hemorrhage.
* **SSRIs/SNRIs:** Increased risk of upper GI bleeding due to impaired platelet aggregation.
* **Methotrexate:** Increased toxicity due to reduced renal excretion.
* **Ibuprofen:** May interfere with the antiplatelet effect of aspirin; separate doses (take aspirin 30 minutes before or 8 hours after ibuprofen).
## Monitoring
* Monitor hemoglobin/hematocrit for signs of occult blood loss.
* Monitor for signs of salicylism (tinnitus, headache, confusion).
* Baseline and periodic Renal Function (SCr/BUN) in high-risk patients.
## Clinical Pearls
* **Acute Setting:** Enteric-coated formulations have a delayed onset of action. In acute coronary syndrome emergencies, **non-enteric coated aspirin** is preferred to allow faster absorption through the buccal mucosa or rapid dissolution in the stomach.
* **Compliance:** Stress the importance of daily adherence for secondary cardiovascular prevention.
* **Geriatrics:** High sensitivity to gastric irritation; consider PPI co-therapy if risk factors for GI bleed are present.
***
**Disclaimer:** This information is for educational purposes and does not replace professional medical judgment. Always verify current prescribing information, institutional protocols, and patient-specific factors before administering medication.
